....referenced the same earlier...if accurate,it is a high bar for us and our only advantage might be the antiviral pathway MOA which might lend itself to easier delivery..pill or inhaler..than infusion
had the same feeling about my IPIX $$$$ projections
Effective antivirals are highly sought after at the moment. I do wish brilacidin was in mild to moderate trial versus the moderate to severe. The focus in a mild to moderate trial might have highlighted the possible reduction in the viral load versus the moderate to severe trial focusing on recovery and mortality with viral load being a secondary endpoint.
Market Data 
Markets 
AI
